Clinical Trial Update: A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 bridging study comparing PF-06439535 plus paclitaxel-carboplatin versus bevacizumab plus paclitaxel-carboplatin in advanced non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• PF-06439535

Snippet

Sponsor: Pfizer | Conditions: Advanced Non-squamous NSCLC | Phase 3 | Status: TERMINATED | Results posted: 2024-10-01